Dimethyl-2-oxo-3,3-propanoheptylphosphonat | 58148-21-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机膦酸及其衍生物
• 英文名称: Dimethyl-2-oxo-3,3-propanoheptylphosphonat
• 英文别名: dimethyl 2-(1-butylcyclobutyl)-2-oxoethylphosphonate；Dimethyl 2-oxo-3,3-propanoheptyl phosphonate；1-(1-butylcyclobutyl)-2-dimethoxyphosphorylethanone
• CAS: 58148-21-3
• 化学式: C₁₂H₂₃O₄P
• 分子量: 262.286
• InChiKey: MNGUXXOQOVTHKC-UHFFFAOYSA-N

物化性质

• 沸点：
  345.6±25.0 °C(Predicted)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  17
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  52.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  Dimethyl-2-oxo-3,3-propanoheptylphosphonat 在 sodium tetrahydroborate 、 sodium hydride 作用下， 以 四氢呋喃 、 甲醇 、 溶剂黄146 为溶剂， 生成
  参考文献：
  名称：

  Discovery of highly potent dual EP 2 and EP 3 agonists with subtype selectivity

  摘要：

  The cyclic carbamate derivatives, 2-{[2-((4S)-4-{(1E,3R)-8-fluoro-3-hydroxy-4,4-dimethyl-1-octenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (5) and 2-{[2-((4S)-4-{(1E,3R)-3-[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (7) were identified as the first potent dual EP2 and EP3 agonists with selectivity against the EP1 and EP4 subtypes. Compounds 5 and 7 demonstrated highly potent dual EP2 and EP3 agonist activity with EC50 values of 10 nM or less. In addition, these compounds possess structural features distinct from natural prostaglandins, such as a cyclic carbamate moiety, a dimethyl or cyclobutyl group and a terminal fluorine atom. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.039
• 作为产物：
  描述：

  1-丁基环丁烷羧酸 在 正丁基锂 、 氯化亚砜 作用下， 以 四氢呋喃 为溶剂， 生成 Dimethyl-2-oxo-3,3-propanoheptylphosphonat
  参考文献：
  名称：

  Discovery of highly potent dual EP 2 and EP 3 agonists with subtype selectivity

  摘要：

  The cyclic carbamate derivatives, 2-{[2-((4S)-4-{(1E,3R)-8-fluoro-3-hydroxy-4,4-dimethyl-1-octenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (5) and 2-{[2-((4S)-4-{(1E,3R)-3-[1-(4-fluorobutyl)cyclobutyl]-3-hydroxy-1-propenyl}-2-oxo-1,3-oxazolidin-3-yl)ethyl]sulfanyl}-1,3-thiazole-4-carboxylic acid (7) were identified as the first potent dual EP2 and EP3 agonists with selectivity against the EP1 and EP4 subtypes. Compounds 5 and 7 demonstrated highly potent dual EP2 and EP3 agonist activity with EC50 values of 10 nM or less. In addition, these compounds possess structural features distinct from natural prostaglandins, such as a cyclic carbamate moiety, a dimethyl or cyclobutyl group and a terminal fluorine atom. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2015.12.039

文献信息

• 15-Cyclobutyl-prostaglandins
  申请人：Ono Pharmaceutical Company

  公开号：US04117119A1

  公开（公告）日：1978-09-26

  Prostaglandin analogues of the formula: ##STR1## wherein A represents a grouping of the formula: ##STR2## X represents trans-vinylene or ethylene and Y represents cis-vinylene or ethylene, R represents hydrogen or alkyl of 1 through 12 carbon atoms, R.sup.1, R.sup.2 and R.sup.3 represent hydrogen, or alkyl of 1 through 12 carbon atoms or an aryl group, with the proviso that at least one of the symbols R.sup.1, R.sup.2 and R.sup.3 represents an alkyl or aryl group, are new compounds possessing useful pharmacological properties; they are especially useful for the treatment of gastric ulceration.

  前列腺素类似物的化学式为：其中A代表的是化学式的一个基团：X代表反式-乙烯基或乙烯基，Y代表顺式-乙烯基或乙烯基，R代表氢或1至12个碳原子的烷基，R.sup.1、R.sup.2和R.sup.3代表氢，或1至12个碳原子的烷基或芳基，但至少其中一个符号R.sup.1、R.sup.2和R.sup.3代表烷基或芳基，这些是具有有用药理特性的新化合物；它们特别适用于治疗胃溃疡。
• Gamma lactams as prostaglandin agonists and use thereof
  申请人：Araldi Luca Gian

  公开号：US20050288357A1

  公开（公告）日：2005-12-29

  1,2-substituted 5-pyrrolidinone compounds are provided, and methods of treatment and pharmaceutical composition that utilize or comprise one or more such compounds. Compounds of the invention are useful for a variety of therapies, including treating or preventing preterm labor, dysmenorrhea, asthma, hypertension, infertility or fertility disorder, undesired blood clotting, preeclampsia or eclampsia, an eosinophil disorder, sexual dysfunction, osteporosis and other destructive bone disease or disorder, renal dysfunction, an immune deficiency disorder, dry eye, ichthyosis, elevated intraocular pressure, sleep disorder, or gastric ulcer, inflammatory disorders and other diseases and disorders associated with the prostaglandin family of compounds.

  本发明提供了1,2-取代的5-吡咯烷酮化合物，并提供了利用或包含一个或多个此类化合物的治疗方法和制药组合物。本发明的化合物可用于各种治疗方案，包括治疗或预防早产、痛经、哮喘、高血压、不孕或生育障碍、不良血液凝固、先兆子痫或子痫、嗜酸性粒细胞异常、性功能障碍、骨质疏松和其他骨骼疾病或障碍、肾功能障碍、免疫缺陷性疾病、干眼症、鱼鳞病、眼内压升高、睡眠障碍或胃溃疡、炎症性疾病和其他与前列腺素类化合物有关的疾病和障碍。
• Synthesis and evaluation of a γ-lactam as a highly selective EP2 and EP4 receptor agonist
  作者：Yufang Xiao、Gian Luca Araldi、Zhong Zhao、Adulla Reddy、Srinivasa Karra、Nadia Brugger、David Fischer、Elizabeth Palmer、Bagna Bao、Sean D. Mckenna

  DOI：10.1016/j.bmcl.2007.11.020

  日期：2008.1

  gamma-Lactam analogs (2) of EP4 receptor agonists were identified by substitution of the pyrazolidinone ring (1) with a pyrrolidinone ring. Several compounds (such as 2a, 2h) with high potency, selectivity and acceptable PK profiles were discovered. These were assessed in animal models of ovulation induction and bronchoconstriction. (c) 2007 Elsevier Ltd. All rights reserved.
• [EN] GAMMA LACTAMS AS PROSTAGLANDIN AGONISTS AND USE THEREOF<br/>[FR] GAMMA LACTAMES UTILISES EN TANT QU'AGONISTES DE LA PROSTAGLANDINE ET LEUR UTILISATION
  申请人：——

  公开号：WO2003103604A3

  公开（公告）日：2004-02-12
• US4045468A
  申请人：——

  公开号：US4045468A

  公开（公告）日：1977-08-30